Kyntra Bio (KYNB)
Develops CD46-targeted cancer therapies and roxadustat for anemia in lower-risk myelodysplastic syndromes.
$7.26
vs last close−0.02 (−0.34%)
Something off on this page? Send us feedback.
Next report
Nov 9, 26
in 47 days
EPS estimate
−$3.73
Revenue estimate
$1.8M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$4.50$0.05−$3.38−$1.61−$3.51−$3.74$2.96Pending
Estimate−$2.00$0.75−$2.25−$4.01−$3.89−$3.36−$3.18−$3.73
Surprise−125.0%−93.3%−50.2%+59.9%+9.8%−11.3%+193.1%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$3.1M$2.7M$1.3M$1.1M$1.3M$3.7M−$1.5MPending
Estimate$24.9M$1.6M$2.6M$2.4M$1.7M$1.6M$2.1M$1.8M
Surprise−87.4%+68.8%−50.6%−55.8%−22.2%+137.9%−171.8%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | −$2.90 | — | — |
| Sep 2028 | −$2.93 | — | — |
| Jun 2028 | −$2.96 | — | — |
| Mar 2028 | −$2.99 | — | — |
| Dec 2027 | −$2.99 | — | — |
| Sep 2027 | −$3.05 | — | — |
| Jun 2027 | −$3.08 | — | — |
| Mar 2027 | −$2.84 | — | — |
| Dec 2026 | −$5.07 | — | — |
| Nov 2026 | −$3.73 | — | — |
| Aug 2026 | −$3.18 | $2.96 | +193.1% |
| May 2026 | −$3.36 | −$3.74 | −11.3% |
| Mar 2026 | −$3.89 | −$3.51 | +9.8% |
| Nov 2025 | −$4.01 | −$1.61 | +59.9% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | −$2.90 | — | — | $1.3M | — | — | — |
| Sep 2028 | −$2.93 | — | — | $1.3M | — | — | — |
| Jun 2028 | −$2.96 | — | — | $1.3M | — | — | — |
| Mar 2028 | −$2.99 | — | — | $1.3M | — | — | — |
| Dec 2027 | −$2.99 | — | — | $1.3M | — | — | — |
| Sep 2027 | −$3.05 | — | — | $1.3M | — | — | — |
| Jun 2027 | −$3.08 | — | — | $1.3M | — | — | — |
| Mar 2027 | −$2.84 | — | — | $1.3M | — | — | — |
| Dec 2026 | −$5.07 | — | — | $2.5M | — | — | — |
| Nov 9, 2026 | −$3.73 | — | — | $1.8M | — | — | — |
| Aug 13, 2026 | −$3.18 | $2.96 | +193.1% | $2.1M | −$1.5M | −171.8% | +0.1% |
| May 11, 2026 | −$3.36 | −$3.74 | −11.3% | $1.6M | $3.7M | +137.9% | +6.3% |
| Mar 16, 2026 | −$3.89 | −$3.51 | +9.8% | $1.7M | $1.3M | −22.2% | +5.3% |
| Nov 10, 2025 | −$4.01 | −$1.61 | +59.9% | $2.4M | $1.1M | −55.8% | −9.6% |
| Aug 11, 2025 | |||||||
| May 12, 2025 | |||||||
| Mar 17, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 6, 2024 | |||||||
| May 6, 2024 | |||||||
| Feb 26, 2024 | |||||||
| Nov 6, 2023 | |||||||
| Aug 7, 2023 | |||||||
| May 8, 2023 | |||||||
| Feb 27, 2023 | |||||||
| Nov 7, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 9, 2022 | |||||||
| Feb 28, 2022 | |||||||
| Nov 9, 2021 | |||||||
| Aug 9, 2021 | |||||||
| May 10, 2021 | |||||||
| Mar 1, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 2, 2020 | |||||||
| Nov 11, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 9, 2019 | |||||||
| Feb 27, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 9, 2018 | |||||||
| Feb 27, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 7, 2017 | |||||||
| May 9, 2017 | |||||||
| Mar 1, 2017 | |||||||
| Nov 8, 2016 | |||||||
| Aug 8, 2016 | |||||||
| May 9, 2016 | |||||||
| Feb 29, 2016 | |||||||
| Nov 12, 2015 | |||||||
| Aug 13, 2015 |